Belgian value-added medicines specialist Hyloris Pharmaceuticals has announced plans to launch an initial public offering that the firm believes will give it the funding it needs to pursue opportunities through the US hybrid 505(b)(2) regulatory pathway.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?